GDRX Quote, Financials, Valuation and Earnings

DarioHealth Corp. has a net margin of 0.57% compared to GoodRx Holdings, Inc.'s net margin of -41.48%. GoodRx Holdings, Inc.'s return on equity of 4.78% beat DarioHealth Corp.'s return on equity of -41.55%.

GoodRx Holdings, Inc. has a consensus price target of $4.74, signalling upside risk potential of 69.26%. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 50.08%. Given that GoodRx Holdings, Inc. has higher upside potential than DarioHealth Corp., analysts believe GoodRx Holdings, Inc. is more attractive than DarioHealth Corp..

GoodRx Holdings, Inc. has a beta of 1.455, which suggesting that the stock is 45.545% more volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.047, suggesting its more volatile than the S&P 500 by 4.689%.

GoodRx Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GoodRx Holdings, Inc. pays -- of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend.

GoodRx Holdings, Inc. quarterly revenues are $196M, which are larger than DarioHealth Corp. quarterly revenues of $5M. GoodRx Holdings, Inc.'s net income of $1.1M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, GoodRx Holdings, Inc.'s price-to-earnings ratio is 32.60x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GoodRx Holdings, Inc. is 1.28x versus 6.75x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Forian, Inc. has a net margin of 0.57% compared to GoodRx Holdings, Inc.'s net margin of -1.95%. GoodRx Holdings, Inc.'s return on equity of 4.78% beat Forian, Inc.'s return on equity of -2.86%.

GoodRx Holdings, Inc. has a consensus price target of $4.74, signalling upside risk potential of 69.26%. On the other hand Forian, Inc. has an analysts' consensus of $2.10 which suggests that it could grow by 0.96%. Given that GoodRx Holdings, Inc. has higher upside potential than Forian, Inc., analysts believe GoodRx Holdings, Inc. is more attractive than Forian, Inc..

GoodRx Holdings, Inc. has a beta of 1.455, which suggesting that the stock is 45.545% more volatile than S&P 500. In comparison Forian, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GoodRx Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Forian, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GoodRx Holdings, Inc. pays -- of its earnings as a dividend. Forian, Inc. pays out -- of its earnings as a dividend.

GoodRx Holdings, Inc. quarterly revenues are $196M, which are larger than Forian, Inc. quarterly revenues of $7.8M. GoodRx Holdings, Inc.'s net income of $1.1M is higher than Forian, Inc.'s net income of -$151.2K. Notably, GoodRx Holdings, Inc.'s price-to-earnings ratio is 32.60x while Forian, Inc.'s PE ratio is 49.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GoodRx Holdings, Inc. is 1.28x versus 2.30x for Forian, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of 0.57% compared to GoodRx Holdings, Inc.'s net margin of 11.54%. GoodRx Holdings, Inc.'s return on equity of 4.78% beat National Research Corp.'s return on equity of 61.55%.

GoodRx Holdings, Inc. has a consensus price target of $4.74, signalling upside risk potential of 69.26%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that GoodRx Holdings, Inc. has higher upside potential than National Research Corp., analysts believe GoodRx Holdings, Inc. is more attractive than National Research Corp..

GoodRx Holdings, Inc. has a beta of 1.455, which suggesting that the stock is 45.545% more volatile than S&P 500. In comparison National Research Corp. has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.662%.

GoodRx Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 2.64% to investors and pays a quarterly dividend of $0.16 per share. GoodRx Holdings, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GoodRx Holdings, Inc. quarterly revenues are $196M, which are larger than National Research Corp. quarterly revenues of $34.6M. GoodRx Holdings, Inc.'s net income of $1.1M is lower than National Research Corp.'s net income of $4M. Notably, GoodRx Holdings, Inc.'s price-to-earnings ratio is 32.60x while National Research Corp.'s PE ratio is 27.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GoodRx Holdings, Inc. is 1.28x versus 3.23x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of 0.57% compared to GoodRx Holdings, Inc.'s net margin of 9.46%. GoodRx Holdings, Inc.'s return on equity of 4.78% beat Spok Holdings, Inc.'s return on equity of 10.88%.

GoodRx Holdings, Inc. has a consensus price target of $4.74, signalling upside risk potential of 69.26%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.66%. Given that GoodRx Holdings, Inc. has higher upside potential than Spok Holdings, Inc., analysts believe GoodRx Holdings, Inc. is more attractive than Spok Holdings, Inc..

GoodRx Holdings, Inc. has a beta of 1.455, which suggesting that the stock is 45.545% more volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.432%.

GoodRx Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.62% to investors and pays a quarterly dividend of $0.31 per share. GoodRx Holdings, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

GoodRx Holdings, Inc. quarterly revenues are $196M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. GoodRx Holdings, Inc.'s net income of $1.1M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, GoodRx Holdings, Inc.'s price-to-earnings ratio is 32.60x while Spok Holdings, Inc.'s PE ratio is 16.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GoodRx Holdings, Inc. is 1.28x versus 1.93x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.